Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2021-12-02 Major Shareholding Noti…
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021
Major Shareholding Notification Classification · 100% confidence The document is a 'Standard form for notification of major holdings' regarding Zealand Pharma A/S. It details the acquisition of voting rights and share capital by The Capital Group Companies, Inc., crossing a specific threshold. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ), which tracks changes in significant ownership levels.
2021-12-02 English
Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021
Major Shareholding Notification Classification · 100% confidence The document is a 'Standard form for notification of major holdings' regarding Zealand Pharma A/S. It explicitly details the acquisition/disposal of voting rights and share capital by SMALLCAP World Fund, Inc., crossing a specific threshold. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2021-12-02 English
Total number of shares and voting rights in Zealand Pharma at November 30, 2021
Share Issue/Capital Change Classification · 75% confidence The document is a company announcement disclosing the total number of shares and voting rights following an employee warrant exercise, i.e., a change in share capital. It is not a full financial report, call transcript, or dividend notice, but a notification of a capital change. Therefore it falls under “Share Issue/Capital Change” (SHA).
2021-12-01 English
Earnings Release 2021
Earnings Release Classification · 95% confidence The document is a press release titled "Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide". It details topline results from a clinical trial, including safety, tolerability, pharmacokinetics, and pharmacodynamics, and discusses future development plans. This content structure—announcing key results from a specific period or trial phase—is characteristic of an Earnings Release (ER) or a general announcement of significant operational news. Since it is not a full quarterly/annual report (10-K or IR), nor a transcript (CT), nor a formal presentation (IP), and it focuses on immediate financial/operational results, the best fit among the provided options is 'Earnings Release' (ER), as clinical trial success is a major driver of investor interest and often accompanies or precedes formal earnings reports. Given the context of a biotechnology company, clinical trial updates are treated as material operational news akin to earnings highlights. It is not a Report Publication Announcement (RPA) because it contains the substantive results, not just a notice that a report is available. FY 2021
2021-11-22 English
Share Issue/Capital Change 2021
Share Issue/Capital Change Classification · 98% confidence The document is a company announcement (No. 69/2021) dated November 19, 2021, explicitly stating that 'Zealand Pharma increases its share capital as a consequence of exercise of employee warrants.' The text details the issuance of 47,045 new shares due to warrant exercises, the total proceeds, and the resulting change in the total share capital. This action directly relates to changes in the company's capital structure resulting from employee compensation/incentive plans being exercised, which leads to an increase in issued shares. This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). It is not a general earnings release (ER), a full annual report (10-K), or a simple dividend notice (DIV).
2021-11-19 English
Earnings Release 2021
Earnings Release Classification · 100% confidence The document explicitly states it is an "Interim report for 9M 2021" and presents detailed "Financial results for the first nine months of 2021," including revenue, expenses, and cash positions as of September 30, 2021. This content structure—a comprehensive financial report covering a period shorter than a full year (nine months)—is the defining characteristic of an Interim or Quarterly Report. This aligns perfectly with the definition for Interim / Quarterly Report (IR). It is not an Earnings Release (ER) because it is a comprehensive report, not just the initial highlights, and it is not a 10-K as it covers only nine months. 9M 2021
2021-11-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.